

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Canceled)

Claim 11 (Currently Amended): A method for inhibiting or treating neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury, said method comprising: administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin in combination or conjunction with ~~an effective amount of~~ a second agent selected from the group consisting of a cyclosporin ~~or an immunosuppressive analog thereof~~, an ascomycin ~~or immunosuppressive analog thereof~~, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.

Claim 12 (Currently Amended): The method of Claim 11 wherein the second agent is cyclosporin A, cyclosporin G, or FK-506 ~~or monoclonal antibodies to leukocyte receptors or to their ligands~~.

Claim 13 (Previously Presented): The method of Claim 11 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.

Claim 14 (Previously Presented): The method of Claim 13 wherein the second agent is monoclonal antibodies to CD3.

Claim 15 (Previously Presented): The method of Claim 11 wherein the second agent is cyclosporin A.

Claim 16 (Previously Presented): The method of Claim 11 wherein the second agent is cyclosporin G.

Claim 17 (Previously Presented): The method of Claim 11 wherein the second agent is mycophenolic acid.

Claim 18 (Previously Presented): The method of Claim 11 wherein the second agent is CTLA4Ig.

Claim 19 (Previously Presented): The method of Claim 11 wherein the second agent is mycophenolate mofetil.

Claims 20-28 (Canceled)